ORCHID CHEM concern about future growth looms
http://akprabhakar.blogspot.com/2009/12/orchid-chem-concern-about-future-growth.html
*GLENMARK and JUBILANT Organosys which can see better performance in years
to come.***

ORCHIDCHEM Cmp Rs.199 saw sudden sell-off with volumes after, Orchid
Chemicals & Pharmaceuticals has agreed to sell its injectables business to
the US-based Hospira for around $400 million (Rs 1,850 crore),  a valuation
that represents a 20% premium to the Chennai-based firm’s market value and
greatly boosts its financial flexibility. The acquisition includes Orchid’s
beta-lactam antibiotics manufacturing complex and pharmaceutical research
and development facility at Irungattukottai in Chennai and its generic
injectable product portfolio and pipeline.

[image: ORCHID.JPEG]



Regards

A.K.Prabhakar

 Equity Analyst

[email protected]

[email protected]

* *http://akprabhakar.blogspot.com

http://prabhakar-views.blogspot.com

*Disclaimer:***

*This represents views based purely on Technical studies. The information
and views presented in this report are prepared by A K Prabhakar. The
information contained herein is based on my analysis of the Charts and upon
sources that I consider reliable. I, however, do not vouch for the accuracy
or the completeness thereof. This material is for personal information and I
am not responsible for any loss incurred based upon it. The investments
discussed or recommended in this report may not be suitable for all
investors. Investors must make their own investment decisions based on their
specific investment objectives and financial position and using such
independent advice, as they believe necessary. While acting upon any
information or analysis mentioned in this report, investors may please note
that neither A K Prabhakar nor any person connected with him accepts any
liability arising from the use of this information and views mentioned in
this document. A K Prabhakar and his affiliates may hold long or short
positions in the above-mentioned companies from time to time. The report is
intended for a restricted audience and I am not soliciting any action based
on it. Neither the information nor any opinion expressed herein constitutes
an offer or an invitation to make an offer, to buy or sell any securities,
or any options, futures or other derivatives related to such securities. *

--

You received this message because you are subscribed to the Google Groups 
""GLOBAL SPECULATORS"" group.
To post to this group, send email to [email protected].
To unsubscribe from this group, send email to 
[email protected].
For more options, visit this group at 
http://groups.google.com/group/globalspeculators?hl=en.


<<image001.jpg>>

Reply via email to